Published in J Obes on August 12, 2010
Identification and importance of brown adipose tissue in adult humans. N Engl J Med (2009) 20.57
Cold-activated brown adipose tissue in healthy men. N Engl J Med (2009) 17.58
Unexpected evidence for active brown adipose tissue in adult humans. Am J Physiol Endocrinol Metab (2007) 10.40
Predicting basal metabolic rate, new standards and review of previous work. Hum Nutr Clin Nutr (1985) 10.24
High incidence of metabolically active brown adipose tissue in healthy adult humans: effects of cold exposure and adiposity. Diabetes (2009) 8.81
Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med (2005) 5.35
The presence of UCP1 demonstrates that metabolically active adipose tissue in the neck of adult humans truly represents brown adipose tissue. FASEB J (2009) 4.78
Meta-analysis: the effect of dietary counseling for weight loss. Ann Intern Med (2007) 4.54
Concern Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 4.41
Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess (2004) 3.73
Transcriptional control of brown adipocyte development and physiological function--of mice and men. Genes Dev (2009) 2.66
Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J (2007) 2.56
Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. Am J Clin Nutr (2008) 2.13
The role of brown adipose tissue in human obesity. Nutr Metab Cardiovasc Dis (2006) 1.78
Energy expenditure and fuel selection in biological systems: the theory and practice of calculations based on indirect calorimetry and tracer methods. World Rev Nutr Diet (1992) 1.63
Before they were fat: adipocyte progenitors. Cell Metab (2008) 1.58
Contribution of BAT and skeletal muscle to thermogenesis induced by ephedrine in man. Am J Physiol (1985) 1.56
Validation of a quantitative magnetic resonance method for measuring human body composition. Obesity (Silver Spring) (2008) 1.34
Analysis of gaseous exchange in open-circuit indirect calorimetry. Med Biol Eng Comput (1984) 1.04
Thermogenic effects of sibutramine in humans. Am J Clin Nutr (1998) 1.01
Thermogenic effects of sibutramine and its metabolites. Br J Pharmacol (1999) 0.99
Intra-individual variability and measurement noise in estimates of energy expenditure by whole body indirect calorimetry. Br J Nutr (1987) 0.97
The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial. Int J Obes Relat Metab Disord (1992) 0.97
Repeatability of 24-h energy expenditure measurements in humans by indirect calorimetry. Am J Clin Nutr (1990) 0.97
Acute effect of ephedrine on 24-h energy balance. Clin Sci (Lond) (1999) 0.87
Intra-individual variability and adaptation of overnight- and sleeping metabolic rate. Physiol Behav (2007) 0.86
The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord (1999) 0.86
Effects of sibutramine on resting metabolic rate and weight loss in overweight women. Obes Res (1998) 0.82
Pharmacology of thermogenic drugs. Am J Clin Nutr (1992) 0.80
Influence of sibutramine on energy expenditure in African American women. Obes Res (2001) 0.79
The effect of chronic ephedrine treatment on substrate utilization, the sympathoadrenal activity, and energy expenditure during glucose-induced thermogenesis in man. Metabolism (1986) 0.77
Non-invasive techniques for assessing carbohydrate flux: I. Measurement of depletion by indirect calorimetry. Acta Physiol Scand (1993) 0.77
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (2004) 18.86
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet (2006) 6.50
The architecture of gene regulatory variation across multiple human tissues: the MuTHER study. PLoS Genet (2011) 5.95
Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med (2010) 4.52
A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science (2004) 3.54
Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J (2007) 2.56
Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest (2009) 2.53
Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC. EMBO Mol Med (2009) 1.80
Management of obesity in adults: European clinical practice guidelines. Obes Facts (2008) 1.59
Tamoxifen-induced anorexia is associated with fatty acid synthase inhibition in the ventromedial nucleus of the hypothalamus and accumulation of malonyl-CoA. Diabetes (2006) 1.46
Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial. Diabetes Care (2013) 1.41
Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. J Hypertens (2012) 1.37
Validation of a quantitative magnetic resonance method for measuring human body composition. Obesity (Silver Spring) (2008) 1.34
Mitochondrial dysfunction in patients with primary congenital insulin resistance. J Clin Invest (2011) 1.19
The metabolic profile of early Huntington's disease--a combined human and transgenic mouse study. Exp Neurol (2008) 1.11
Complement abnormalities in acquired lipodystrophy revisited. J Clin Endocrinol Metab (2008) 1.10
Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus. J Clin Pharmacol (2010) 1.05
Feasibility and indicative results from a 12-month low-energy liquid diet treatment and maintenance programme for severe obesity. Br J Gen Pract (2013) 1.04
Energy expenditure and adaptive responses to an acute hypercaloric fat load in humans with lipodystrophy. J Clin Endocrinol Metab (2004) 1.04
Cell proliferation activities on skin fibroblasts from a short child with absence of one copy of the type 1 insulin-like growth factor receptor (IGF1R) gene and a tall child with three copies of the IGF1R gene. J Clin Endocrinol Metab (2003) 0.99
Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study. J Clin Pharmacol (2010) 0.98
Uric acid as a risk factor for cardiovascular disease and mortality in overweight/obese individuals. PLoS One (2013) 0.97
Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. Metabolism (2009) 0.97
Defective peroxisomal proliferators activated receptor gamma activity due to dominant-negative mutation synergizes with hypertension to accelerate cardiac fibrosis in mice. Eur J Heart Fail (2009) 0.94
Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial). Am J Clin Nutr (2003) 0.92
Efficiency of autoregulatory homeostatic responses to imposed caloric excess in lean men. Am J Physiol Endocrinol Metab (2007) 0.91
The comparative effects of bariatric surgery on weight and type 2 diabetes. Obes Surg (2007) 0.91
Early diet and peak bone mass: 20 year follow-up of a randomized trial of early diet in infants born preterm. Bone (2009) 0.89
Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes. Diabetes Care (2012) 0.88
Regional hemodynamic effects of the N-(2-benzoylphenyl)-L-tyrosine peroxisome proliferator-activated receptor-gamma ligand, GI 262570 [(S)-2-(2-benzoylphenylamino)-3-[4-[2-(5-methyl-2-phenyl-2-oxazol-4-yl)ethoxy]phenyl]propionic acid], in conscious rats. J Pharmacol Exp Ther (2004) 0.88
Action on obesity: comprehensive care for all. Clin Med (2013) 0.88
Comparison of narrow-angle fan-beam and pencil-beam densitometers: in vivo and phantom study of the effect of bone density, scan mode, and tissue depth on spine measurements. J Clin Densitom (2004) 0.86
alpha-Tropomyosin mutations Asp(175)Asn and Glu(180)Gly affect cardiac function in transgenic rats in different ways. Am J Physiol Regul Integr Comp Physiol (2004) 0.86
ABC of obesity. Management: part II--drugs. BMJ (2006) 0.85
Engaging patients, clinicians and health funders in weight management: the Counterweight Programme. Fam Pract (2008) 0.85
Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency. Clin Endocrinol (Oxf) (2005) 0.84
Efficacy and safety of CP-945,598, a selective cannabinoid CB1 receptor antagonist, on weight loss and maintenance. Obesity (Silver Spring) (2011) 0.83
Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial. Nutr Metab (Lond) (2009) 0.83
Quantification of lean and fat tissue repletion following critical illness: a case report. Crit Care (2008) 0.83
Mitochondrial oxidative phosphorylation is impaired in patients with congenital lipodystrophy. J Clin Endocrinol Metab (2012) 0.82
Obesity and risk of myocardial infarction: the INTERHEART study. Lancet (2006) 0.82
First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus. BMC Pharmacol Toxicol (2013) 0.82
Reduced T2* values in soleus muscle of patients with type 2 diabetes mellitus. PLoS One (2012) 0.82
Joint scientific statement of the European Association for the Study of Obesity and the European Society of Hypertension: Obesity and early vascular ageing. J Hypertens (2015) 0.82
Net protein oxidation is adapted to dietary protein intake in domestic cats (Felis silvestris catus). J Nutr (2002) 0.81
Quantitative magnetic resonance (QMR) for longitudinal evaluation of body composition changes with two dietary regimens. Obesity (Silver Spring) (2009) 0.81
Breast-feeding and formula feeding in healthy term infants and bone health at age 10 years. Br J Nutr (2013) 0.81
Translating metabolic biochemistry into the clinic: an interview with Steve O'Rahilly. Interview by Kathy Weston. Dis Model Mech (2011) 0.81
Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies. Drug Metab Dispos (2012) 0.80
Early response to sibutramine in patients not meeting current label criteria: preliminary analysis of SCOUT lead-in period. Obesity (Silver Spring) (2009) 0.80
The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in period. BMC Endocr Disord (2010) 0.79
Intramyocellular lipid levels are associated with peripheral, but not hepatic, insulin sensitivity in normal healthy subjects. Clin Sci (Lond) (2009) 0.79
Criteria for EASO-collaborating centres for obesity management. Obes Facts (2011) 0.78
Withdrawal of sibutramine. Editorial is judgment in advance of the facts. BMJ (2010) 0.77
The Eating Disorder Inventory in a UK National Health Service Obesity Clinic and its response to modest weight loss. Eat Behav (2002) 0.77
Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial. J Cardiovasc Pharmacol (2008) 0.77
Latent autoimmune diabetes in adults presenting as diabetes "recurrence" after bariatric surgery: a case report. Diabetes Care (2013) 0.77
Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. J Hypertens (2014) 0.77
Growth hormone (GH) replacement therapy in GH deficient adults: predictors of one-year metabolic and clinical response. Growth Horm IGF Res (2007) 0.76
Aspartame and its effects on health: approach seems simplistic in electronic responses to editorial. BMJ (2005) 0.75
Emerging pharmacotherapy for treating obesity and associated cardiometabolic risk. Asia Pac J Clin Nutr (2006) 0.75
Obesity Management in Europe: Current Status and Objectives for the Future. Obes Facts (2016) 0.75
Regional gastrointestinal delivery of remogliflozin etabonate in humans. Biopharm Drug Dispos (2013) 0.75
A conversation with Stephen O'Rahilly. Interviewed by Ushma S. Neill. J Clin Invest (2013) 0.75
Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and heart failure. J Hypertens (2016) 0.75
Relation between weight loss and causes of death in patients with cardiovascular disease: finding from the SCOUT trial. J Cardiovasc Med (Hagerstown) (2017) 0.75